Methods for treating hair loss disorders

Patent metadata

Field	Value
Publication number	US-11298570-B2
Application number	US-201916299382-A
Country	US
Kind code	B2
Filing date	Mar 12, 2019
Priority date	Nov 2, 2010
Publication date	Apr 12, 2022
Grant date	Apr 12, 2022

Abstract

The invention provides for methods for treating a hair loss disorder in a subject by administering a Janus Kinase/Signal Transducers and Activators of Transcription inhibitor.

First claim

What is claimed:

1. A method of treating a hair loss disorder in a subject in need thereof, the method consisting of: administering to the subject an effective amount of a small molecule janus kinase (JAK) 1 and/or JAK2 inhibitor, wherein the JAK1 and/or JAK2 inhibitor comprises one or more isotopes.

2. The method of claim 1 , wherein the JAK1 and/or JAK2 inhibitor is selected from ruxolitinib (INCB018424), filgotinib (GLPG0634), Tyrphostin B42 (AG490), momelotinib (CYT387), pacritinib (SB1518), baricitinib (LY3009104), AZD1480, fedratinib (TG101348), BMS-911543, and lestaurtinib (CEP-701), a pharmaceutically acceptable salt thereof, or a combination thereof.

3. The method of claim 1 , wherein the hair loss disorder is androgenetic alopecia, telogen effluvium, tinea capitis, patchy alopecia areata, alopecia totalis, hypotrichosis, hereditary hypotrichosis simplex, alopecia universalis, or a combination thereof.

4. The method of claim 1 , wherein the hair loss disorder is alopecia areata.

5. The method of claim 1 , wherein the hair loss disorder is patchy alopecia areata.

6. The method of claim 1 , wherein the hair loss disorder is alopecia totalis.

7. The method of claim 1 , wherein the hair loss disorder is alopecia universalis.

8. The method of claim 1 , wherein the hair loss disorder is androgenetic alopecia.

9. The method of claim 1 , wherein the JAK1 and/or JAK2 inhibitor is administered topically.

10. The method of claim 1 , wherein the JAK1 and/or JAK2 inhibitor is administered orally.

11. The method of claim 1 , wherein the JAK1 and/or JAK2 inhibitor is administered via a route selected from the group consisting of intra-muscular injection, intra-peritoneal injection, an infusion, intravenous, intradermal, subcutaneous, oral, inhalation, transdermal, topical, transmucosal, nasal, rectal, and a combination thereof.

12. The method of claim 1 , wherein the JAK1 and/or JAK2 inhibitor is administered in a pharmaceutical composition selected from the group consisting of a solution, suspension, capsule, tablet, pill, troche, nasal spray, suppository, ointment, salve, gel, or cream.

13. The method of claim 1 , wherein administering to the human occurs twice daily, daily, weekly, twice weekly, monthly, twice monthly, yearly, 1 time per week, 2 times per week, 3 times per week, 4 times per week, 5 times per week, 6 times per week, 7 times per week, 8 times per week, 9 times per week, 10 times per week, 11 times per week, 12 times per week, 13 times per week, or 14 times per week.

14. The method of claim 1 , wherein treating a hair loss disorder is by inducing hair growth.

15. The method of claim 1 , wherein the compound is suitable for nuclear magnetic resonance (NMR).

16. The method of claim 1 , wherein the one or more isotopes is a radioisotope.

17. The method of claim 1 , wherein the one or more isotopes are isotopes of carbon or hydrogen.

18. The method of claim 17 , wherein the hair loss disorder is patchy alopecia areata.

19. The method of claim 17 , wherein the hair loss disorder is alopecia totalis.

20. The method of claim 17 , wherein the hair loss disorder is alopecia universalis.

21. The method of claim 17 , wherein the JAK1 and/or JAK2 inhibitor is administered topically.

22. The method of claim 17 , wherein JAK1 and/or JAK2 inhibitor is administered orally.

23. The method of claim 17 , wherein the JAK1 and/or JAK2 inhibitor is suitable for NMR.

24. The method of claim 1 , wherein the effective amount of the JAK1 and/or JAK2 inhibitor administered to the subject is selected from about 0.0001 μg/kg body weight, about 0.00025 μg/kg body weight, about 0.0005 μg/kg body weight, about 0.00075 μg/kg body weight, about 0.001 μg/kg body weight, about 0.0025 μg/kg body weight, about 0.005 μg/kg body weight, about 0.0075 μg/kg body weight, about 0.01 μg/kg body weight, about 0.025 μg/kg body weight, about 0.05 μg/kg body weight, about 0.075 μg/kg body weight, about 0.1 μg/kg body weight, about 0.25 μg/kg body weight, about 0.5 μg/kg body weight, about 0.75 μg/kg body weight, about 1 μg/kg body weight, about 5 μg/kg body weight, about 10 μg/kg body weight, about 25 μg/kg body weight, about 50 μg/kg body weight, about 75 μg/kg body weight, about 100 μg/kg body weight, about 150 μg/kg body weight, about 200 μg/kg body weight, about 250 μg/kg body weight, about 300 μg/kg body weight, about 350 μg/kg body weight, about 400 μg/kg body weight, about 450 μg/kg body weight, about 500 μg/kg body weight, about 550 μg/kg body weight, about 600 μg/kg body weight, about 650 μg/kg body weight, about 700 μg/kg body weight, about 750 μg/kg body weight, about 800 μg/kg body weight, about 850 μg/kg body weight, about 900 μg/kg body weight, about 950 μg/kg body weight, about 1000 μg/kg body weight, about 2000 μg/kg body weight, about 3000 μg/kg body weight, about 4000 μg/kg body weight, about 5000 μg/kg body weight, about 6000 μg/kg body weight, about 7000 μg/kg body weight, about 8000 μg/kg body weight, about 95000 μg/kg body weight, or about 10,000 μg/kg body weight, about 1 mg/kg body weight, about 1.5 mg/kg body weight, about 2 mg/kg body weight, about 2.5 mg/kg body weight, about 3 mg/kg body weight, about 3.5 mg/kg body weight, about 4 mg/kg body weight, about 4.5 mg/kg body weight, about 5 mg/kg body weight, about 5.5 mg/kg body weight, about 6 mg/kg body weight, about 6.5 mg/kg body weight, about 7 mg/kg body weight, about 7.5 mg/kg body weight, about 8 mg/kg body weight, about 9.5 mg/kg body weight, about 10 mg/kg body weight, about 10.5 mg/kg body weight, about 11.0 mg/kg body weight, about 11.5 mg/kg body weight, about 12 mg/kg body weight, about 12.5 mg/kg body weight, about 13 mg/kg body weight, about 13.5 mg/kg body weight, about 14 mg/kg body weight, about 14.5 mg/kg body weight, about 15 mg/kg body weight, about 15.5 mg/kg body weight, about 16 mg/kg body weight, about 16.5 mg/kg body weight, about 17 mg/kg body weight, about 17.5 mg/kg body weight, about 18 mg/kg body weight, about 19.5 mg/kg body weight, about 20 mg/kg body weight, about 21.5 mg/kg body weight, about 22 mg/kg body weight, about 22.5 mg/kg body weight, about 23 mg/kg body weight, about 23.5 mg/kg body weight, about 24 mg/kg body weight, about 24.5 mg/kg body weight, about 25 mg/kg body weight, about 25.5 mg/kg body weight, about 26 mg/kg body weight, about 26.5 mg/kg body weight, about 27 mg/kg body weight, about 27.5 mg/kg body weight, about 28 mg/kg body weight, about 29.5 mg/kg body weight, or about 30 mg/kg body weight.

25. The method of claim 1 , wherein administering to the subject occurs for at least 1 week.

Assignees

• Univ Columbia

Inventors

• Christiano Angela M
• Clynes Raphael

Classifications

• A61K31/713 Primary

  Double-stranded nucleic acids or oligonucleotides · CPC title

• A61K8/4953

  containing pyrimidine ring derivatives, e.g. minoxidil · CPC title

• A61K8/41

  Amines · CPC title

• A61K8/64

  Proteins; Peptides; Derivatives or degradation products thereof · CPC title

• A61K31/277

  having a ring, e.g. verapamil · CPC title